BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20443648)

  • 1. Morphine/naltrexone.
    Duggan ST; Scott LJ
    CNS Drugs; 2010 Jun; 24(6):527-38. PubMed ID: 20443648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study.
    Stauffer J; Setnik B; Sokolowska M; Romach M; Johnson F; Sellers E
    Clin Drug Investig; 2009; 29(12):777-90. PubMed ID: 19888784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety.
    Katz N; Sun S; Johnson F; Stauffer J
    J Pain; 2010 Apr; 11(4):303-11. PubMed ID: 19944650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A morphine/naltrexone combination (Embeda) for pain.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):22-3. PubMed ID: 20336033
    [No Abstract]   [Full Text] [Related]  

  • 6. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.
    Katz N; Hale M; Morris D; Stauffer J
    Postgrad Med; 2010 Jul; 122(4):112-28. PubMed ID: 20675975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
    Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
    J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.
    Badalamenti VC; Buckley JW; Smith ET
    J Opioid Manag; 2012; 8(2):115-25. PubMed ID: 22616317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
    Webster LR; Johnson FK; Stauffer J; Setnik B; Ciric S
    Drugs R D; 2011 Sep; 11(3):259-75. PubMed ID: 21902287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study.
    Hamann S; Sloan P
    J Opioid Manag; 2007; 3(3):137-44. PubMed ID: 18027539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.
    Smith HS
    Expert Opin Pharmacother; 2011 May; 12(7):1111-25. PubMed ID: 21470065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users.
    Setnik B; Sommerville K; Goli V; Han L; Webster L
    Pain Med; 2013 Aug; 14(8):1173-86. PubMed ID: 23745947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
    Johnson F; Setnik B
    Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.
    Webster LR; Brewer R; Morris D; Cleveland JM; Setnik B
    Postgrad Med; 2011 Sep; 123(5):155-64. PubMed ID: 21904098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
    Johnson FK; Ciric S; Boudriau S; Kisicki J; Stauffer J
    J Clin Pharmacol; 2012 May; 52(5):747-56. PubMed ID: 21593282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature.
    Ruan X; Chen T; Gudin J; Couch JP; Chiravuri S
    J Opioid Manag; 2010; 6(4):300-3. PubMed ID: 20862910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
    Ruan X
    Expert Opin Pharmacother; 2011 May; 12(7):999-1001. PubMed ID: 21470064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade.
    Bashaw ED; Kaiko RF; Grandy RP; Reder RF; Goldenheim PD
    Int J Clin Pharmacol Ther; 1995 Sep; 33(9):524-9. PubMed ID: 8520812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.